123673-33-6

Basic information

• Product Name: 17(S)-HpDoHE
• Synonyms: 17(S)-HpDoHE;17(S)-HpDHA;BNHQALRBDJVUQB-YTQNUIGOSA-N
• CAS NO: 123673-33-6
• Molecular Formula: C22H32O4
• Molecular Weight: 360.48708
• Mol File: 123673-33-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 17(S)-HpDoHE(CAS DataBase Reference)
• NIST Chemistry Reference: 17(S)-HpDoHE(123673-33-6)
• EPA Substance Registry System: 17(S)-HpDoHE(123673-33-6)

Safety Data

• Hazardous Substances Data: 123673-33-6(Hazardous Substances Data)

Usage

Description

17(S)-HpDHA is a mono-oxygenation product of docosahexaenoic acid in human whole blood, human leukocytes, human glial cells, and mouse brain. 17(S)-HpDHA is generally reduced to 17(S)-HDHA , a compound that serves as a precursor to 17(S)-resolvins. 17(S)-HDHA has been shown to inhibit TNF-α-induced interleukin-1β expression in human glioma cells and inhibit TNF-α-induced leukocyte trafficking to the murine air pouch.

Upstream product

• 6217-54-5 docosahexaenoic acid 
• 149234-03-7 4,5-dehydro-DHA 

Downstream Products

• 92693-03-3 (17S)-HDHA 

Relevant articles and documents

USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA

The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful ;isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.